Your browser doesn't support javascript.
loading
Clinical Characteristics of Irritant-Induced Occupational Asthma.
Lantto, Jussi; Suojalehto, Hille; Karvala, Kirsi; Remes, Jouko; Soini, Satu; Suuronen, Katri; Lindström, Irmeli.
Afiliación
  • Lantto J; Doctoral Program in Clinical Research, University of Helsinki, Helsinki, Finland; Finnish Institute of Occupational Health, Occupational Medicine, Helsinki, Finland. Electronic address: jussi.lantto@helsinki.fi.
  • Suojalehto H; Finnish Institute of Occupational Health, Occupational Medicine, Helsinki, Finland.
  • Karvala K; Finnish Institute of Occupational Health, Occupational Medicine, Helsinki, Finland; Varma Mutual Pension Insurance Company, Consultant Physicians, Helsinki, Finland.
  • Remes J; Finnish Institute of Occupational Health, Occupational Medicine, Oulu, Finland.
  • Soini S; Finnish Institute of Occupational Health, Occupational Medicine, Oulu, Finland.
  • Suuronen K; Finnish Institute of Occupational Health, Occupational Medicine, Helsinki, Finland.
  • Lindström I; Finnish Institute of Occupational Health, Occupational Medicine, Helsinki, Finland.
J Allergy Clin Immunol Pract ; 10(6): 1554-1561.e7, 2022 06.
Article en En | MEDLINE | ID: mdl-35259533
BACKGROUND: Work is a substantial contributing factor of adult-onset asthma. A subtype of occupational asthma (OA) is caused by irritant agents, but knowledge of the clinical outcomes of irritant-induced asthma (IIA) is incomplete. OBJECTIVES: To evaluate whether the clinical picture of IIA differs from that of sensitizer-induced OA. METHODS: This retrospective study analyzed acute and subacute IIA patients diagnosed in an occupational medicine clinic during 2004 to 2018. Sixty-nine patients fulfilled the inclusion criteria, and their characteristics were analyzed at the time of the diagnosis and 6 months later. The results were compared with those of 2 subgroups of sensitizer-induced OA: 69 high-molecular-weight (HMW) and 89 low-molecular-weight (LMW) agent-induced OA patients. RESULTS: Six months after the diagnosis, 30% of the patients with IIA needed daily short-acting ß-agonists (SABA), 68% were treated with Global Initiative for Asthma, 2020 report (GINA) step 4-5 medication, and 24% of the patients had asthma exacerbation after the first appointment. IIA depicted inferiority to LMW-induced OA in daily need for SABA (odds ratio [OR]: 3.80, 95% confidence interval [CI]: 1.38-10.46), treatment with GINA step 4-5 medication (OR: 2.22, 95% CI: 1.08-4.57), and exacerbation (OR: 3.85, 95% CI: 1.35-11.04). IIA showed poorer results than HMW-induced OA in the latter 2 of these features (OR: 2.49, 95% CI: 1.07-5.79 and OR: 6.29, 95% CI: 1.53-25.83, respectively). CONCLUSIONS: Six months after the OA diagnosis, a significant proportion of the patients with IIA remain symptomatic and the majority of these patients use asthma medications extensively suggesting uncontrolled asthma. The short-term outcomes of IIA appear poorer than that of sensitizer-induced OA.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Exposición Profesional / Asma Ocupacional / Enfermedades Profesionales Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: J Allergy Clin Immunol Pract Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Exposición Profesional / Asma Ocupacional / Enfermedades Profesionales Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: J Allergy Clin Immunol Pract Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos